Effects of the Selective Progesterone Receptor Modulator Asoprisnil on Uterine Artery Blood Flow, Ovarian Activity, and Clinical Symptoms in Patients with Uterine Leiomyomata Scheduled for Hysterectomy

Wilkens, Julia; Chwalisż, Kristof; Han, Cong; Walker, Jane; Cameron, Iain; Ingamells, Susan; Lawrence, Alexandra; Lumsden, Mary Ann; Hapangama, Dharani; Williams, Alistair; Critchley, Hilary O. D.

doi:10.1210/jc.2008-1104

Cited by 97 publications

(81 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5, 10 ve 25 mg/gün dozlarında sırasıyla kanama miktarını %28, %64 ve %83 oranında azaltmaktadır (40). Ayrıca 25 mg dozunda leiomyom volümünde %36 küçülme izlenmektedir (41). Yalnızca progesteron antagonisti olarak etki etmekte ve endometriumda östrojen aktivitesini inhibe etmemektedir (42).…”

Section: Selektif Progesteron Reseptör Modülatörleriunclassified

Medical Treatment of Leiomyomas

Uğurlucan¹,

Demir²,

Yaşa³

et al. 2017

İstanbul Tıp Fakültesi Dergisi

View full text Add to dashboard Cite

ÖZETLeiomyomlar, reprodüktif çağda en sık görülen jinekolojik tümörlerdir. Leiomyomlar çoğu kadında bulunmakla beraber, bazı kadınlarda semptomatik hale gelmektedir. Genetik veya hormonal kökenli olabilirler. Leiomyomların üzerinde östrojen ve progesteron reseptörleri olması, onları hormona duyarlı hale getirmektedir. Leiomyomların ana tedavisi cerrahi olmakla beraber, cerrahi istemeyen veya fertilitesini korumak isteyen kadınlarda medikal tedaviler gündeme gelmektedir. Medikal tedavilerin çıkış noktası, leiomyomların hormona duyarlı olmasıdır. Medikal tedavi seçenekleri arasında gonadotropin-releasing-3 hormon analogları ve antagonistleri, aromataz inhibitörleri ve selektif progesteron reseptör modülatörleri yer almaktadır. Bu tedaviler kanama kontrolünün yanında leiomyom volümünde de küçülme sağlamaktadır. Bu derlemede bu tedavi yöntemlerine değinilecektir. Anahtar Kelimeler: Leiomyom; anormal uterin kanama; selektif progesteron reseptör modülatörleri; ulipristal asetat; anemi ABSTRACTLeiomyomas are the most common benign gynecological tumors observed during the reproductive period. Although, they are exceedingly common, not all are symptomatic. Leiomyomas are of genetic or hormonal origin and have estrogen and progesterone receptors, making them sensitive to hormones. The main treatment for leiomyomas is surgery, but in women who are not willing to undergo surgery or who want to preserve their fertility, medical treatment options may be used. The main basis of medical treatment in leiomyomas are hormones due to positive response to anti-hormonal therapies. Medical treatment options comprise gonadotropin-releasing-hormone agonists and antagonists, aromatase inhibitors, and selective progesterone receptor modulators. In addition to controlling bleeding, these treatment regimens cause a decrease in the volume of the tumor. In this review, treatment options are discussed.

show abstract

Section: Selektif Progesteron Reseptör Modülatörleriunclassified

Medical Treatment of Leiomyomas

Uğurlucan¹,

Demir²,

Yaşa³

et al. 2017

İstanbul Tıp Fakültesi Dergisi

View full text Add to dashboard Cite

show abstract

“…Compared with progesterone, asoprisnil has a high tissue selectivity and higher binding affinity to progesterone receptors [53]. It induces amenorrhea and reduces uterine fibroid volume in a dose-dependent manner [54,55], and it reduces uterine artery blood flow [56]. Asoprisnil has marginal abortifacient activity and no antiglucocorticoid effect [57][58][59][60].…”

Section: Selective Progesterone Receptor Modulatorsmentioning

confidence: 99%

Medical Management of Uterine Fibroids

Parsanezhad

Jahromi

2012

Curr Obstet Gynecol Rep

View full text Add to dashboard Cite

Uterine leiomyomas are the most common benign tumors of the uterus. Though benign, they can affect the quality of life for many women. Compared with the standard surgical treatments, medical therapy is attractive and avoids possible surgery-related complications. No medical therapy currently exists that can induce rapid regression of the myoma and symptoms with minimal side effects without affecting fertility. This review evaluates medical treatments that are currently available for the treatment of uterine fibroids.

show abstract

“…Given the anti-proliferative effects observed in vitro and in vivo for PRAs (Freeburg et al, 2009b;Goyeneche et al, 2007;Ohara et al, 2007;Poole et al, 2006;Tieszen et al, 2011), the broader utility of this class in treating other benign and malignant growth conditions has not gone unnoticed Robertson et al, 1999;Rocereto et al, 2000;Wilkens et al, 2008). In the closely related condition of uterine fibroids, small studies have demonstrated a reduction in myoma volume and uterine bleeding with asoprisnil and RU-486 (Chabbert-Buffet et al, 2005;DeManno et al, 2003;Fiscella et al, 2006).…”

Section: Clinical Evaluation In Healthy Women and Women With Endometrmentioning

confidence: 99%

Progesterone Resistance and Targeting the Progesterone Receptors: A Therapeutic Approach to Endometriosis

Pullen¹

2012

Endometriosis - Basic Concepts and Current Research Trends

View full text Add to dashboard Cite

Effects of the Selective Progesterone Receptor Modulator Asoprisnil on Uterine Artery Blood Flow, Ovarian Activity, and Clinical Symptoms in Patients with Uterine Leiomyomata Scheduled for Hysterectomy

Abstract: Asoprisnil moderately reduced uterine artery blood flow. This effect may contribute in part to the clinical effects of asoprisnil.

Cited by 97 publications

References 35 publications

Medical Treatment of Leiomyomas

Medical Treatment of Leiomyomas

Medical Management of Uterine Fibroids

Progesterone Resistance and Targeting the Progesterone Receptors: A Therapeutic Approach to Endometriosis

Contact Info

Product

Resources

About